The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson’s disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of these, miR‐22‐3p, 20 , 21 , 22 miR‐124‐3p, 23 and miR‐136‐3p 21 , 24 have been identified as deregulated in other PD biomarker studies, further validating current findings and their replicability at different neurological centers.”
From Validation of differentially expressed brain‐enriched microRNAs in the plasma of PD patients (2020) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Predicting effective microRNA target sites in mammalian mRNAs
Agarwal, V., Bell, G. W., Nam, J.-W., & Bartel, D. P. (2015) · eLife · doi:10.7554/elife.05005 · Cited by 7,318
miRBase: annotating high confidence microRNAs using deep sequencing data
Kozomara, A., & Griffiths-Jones, S. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1181 · Cited by 5,073 · cited 1×
“Following, mapped reads were assigned to mature miRNAs using genome annotation data from Ensembl (v84) [58], UCSC (hg38) [57] and miRBase (v21) [59].”
MethodWightman, B., Ha, I., & Ruvkun, G. (1993) · Cell · doi:10.1016/0092-8674(93)90530-4 · Cited by 4,292
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
Teunissen, C. E., Petzold, A., Bennett, J. L., Berven, F. S., Brundin, L., Comabella, M., Franciotta, D., Frederiksen, J. L., Fleming, J. O., Furlan, R., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c47cc2 · Cited by 845 · cited 1×
“CSF samples free of blood were centrifuged (1600 g, 4°C, 15 min), frozen within 30–40 min after the puncture and stored at -80°C according to CSF collection and storage guidelines [55].”
MethodAltered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease
Gui, Y., Liu, H., Zhang, L., Lv, W., & Hu, X. (2015) · Oncotarget · doi:10.18632/oncotarget.6158 · Cited by 552
Burgos, K., Malenica, I., Metpally, R., Courtright, A., Rakela, B., Beach, T., Shill, H., Adler, C., Sabbagh, M., Villa, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094839 · Cited by 385
Multiple organ involvement by alpha-synuclein pathology in lewy body disorders
Gelpi, E., Navarro‐Otano, J., Tolosa, E., Gaig, C., Compta, Y., Rey, M. J., Martí, M. J., Hernández, I., Valldeoriola, F., Reñé, R., et al. (2014) · Movement Disorders · doi:10.1002/mds.25776 · Cited by 361
Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease
Sala Frigerio, C., Lau, P., Salta, E., Tournoy, J., Bossers, K., Vandenberghe, R., Wallin, A., Bjerke, M., Zetterberg, H., Blennow, K., et al. (2013) · Neurology · doi:10.1212/01.wnl.0000437306.37850.22 · Cited by 156
Jani, D., Allinson, J., Berisha, F., Cowan, K. J., Devanarayan, V., Gleason, C., Jeromin, A., Keller, S., Khan, M. U., Nowatzke, B., et al. (2016) · The AAPS Journal · doi:10.1208/s12248-015-9820-y · Cited by 76 · cited 4×
“Quantitative determination of selected markers was done by ELISA following manufacturer’s guidelines and validated fit-for-purpose as proposed by Jani et al [60].”
MethodInfluential
Research works printed but not linked: 52
- Visser, 2015, Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases, Nat Rev Neurol, 11, 41, 10.1038/nrneurol.2014.232 · DOI · Paper page
- Lang, 2017, Parkinson disease, Nat Rev Dis Primers, 3, 17013, 10.1038/nrdp.2017.13 · DOI · Paper page
- Halliday, 2014, Alpha-synuclein biology in Lewy body diseases, Alzheimers Res Ther, 6, 73, 10.1186/s13195-014-0073-2 · DOI · Paper page
- Kulisevsky, 2012, Cognitive impairment and dementia in Parkinson’s disease, Neurobiol Dis, 46, 590, 10.1016/j.nbd.2012.03.029 · DOI · Paper page
- Elton, 1987, Unified Parkinson’s disease rating scale, Recent Developments in Parkinson’s Disease: Macmillan Health Care Information), 293
- Seitelberger, 1973, Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations, J Neurol Sci, 20, 415, 10.1016/0022-510X(73)90175-5 · DOI · Paper page
- Bartus, 2013, Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease, Brain, 136, 2419, 10.1093/brain/awt192 · DOI · Paper page
- van de Berg, 2016, Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease, Mol Neurodegener, 11, 7, 10.1186/s13024-016-0072-9 · DOI · Paper page
- Kotzbauer, 2015, Correlation Between Decreased CSF α-Synuclein and Aβ(1-42) in Parkinson Disease, Neurobiol Aging, 36, 476, 10.1016/j.neurobiolaging.2014.07.043 · DOI
- Verbeek, 2014, CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls, Parkinsonism Relat Disord, 20, 112, 10.1016/j.parkreldis.2013.09.003 · DOI
- Fox, 2015, Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay, Mol Neurodegener, 10, 64, 10.1186/s13024-015-0059-y · DOI · Paper page
- Tambasco, 2014, Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson’s disease, Mov Disord, 29, 1019, 10.1002/mds.25772 · DOI · Paper page
- Calabresi, 2014, Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson’s Disease, Front Aging Neurosci, 6, 53
- da Costa, 2016, Recent developments in circulating biomarkers in Parkinson’s disease: the potential use of miRNAs in a clinical setting, Bioanalysis, 8, 2497, 10.4155/bio-2016-0166 · DOI
- Bartel, 2004, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 · DOI
- Gage, 2006, Noncoding RNAs in the mammalian central nervous system, Annu Rev Neurosci, 29, 77, 10.1146/annurev.neuro.29.051605.112839 · DOI · Paper page
- Lotvall, 2007, Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, Nat Cell Biol, 9, 654, 10.1038/ncb1596 · DOI · Paper page
- Sonntag, 2010, MicroRNAs and deregulated gene expression networks in neurodegeneration, Brain Res, 1338, 48, 10.1016/j.brainres.2010.03.106 · DOI
- Dawson, 2009, Understanding microRNAs in neurodegeneration, Nat Rev Neurosci, 10, 837, 10.1038/nrn2726 · DOI · Paper page
- Zetterberg, 2014, Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions, J Neurol Neurosurg Psychiatry, 85, 1065, 10.1136/jnnp-2013-307539 · DOI
- Papavassiliou, 2013, MicroRNAs: Novel diagnostic and prognostic biomarkers in atherosclerosis, Curr Top Med Chem, 13, 1503, 10.2174/15680266113139990099 · DOI
- Vachev, 2015, Circulating microRNAs as a Novel Class of Potential Diagnostic Biomarkers in Neuropsychiatric Disorders, Folia Med (Plovdiv), 57, 159
- Hagman, 2017, Circulating microRNAs as biomarkers in progressive multiple sclerosis, Mult Scler, 23, 403, 10.1177/1352458516651141 · DOI
- Bahnassey, 2016, Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection, Tumour Biol, 37, 12273, 10.1007/s13277-016-5097-8 · DOI
- Kordower, 2015, The prion hypothesis of Parkinson’s disease, Curr Neurol Neurosci Rep, 15, 28, 10.1007/s11910-015-0549-x · DOI
- Franco, 2017, Metabolic Dysfunction in Parkinson’s Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism, Brain Res Bull, 133, 12, 10.1016/j.brainresbull.2017.03.009 · DOI · Paper page
- McLean, 2012, Protein degradation pathways in Parkinson’s disease: curse or blessing, Acta Neuropathol, 124, 153, 10.1007/s00401-012-1004-6 · DOI · Paper page
- Petrucelli, 2012, Disruption of protein quality control in Parkinson’s disease, Cold Spring Harb Perspect Med, 2, a009423
- Jozwiak, 2017, Parkin, PINK1 and DJ1 as possible modulators of mTOR pathway in ganglioglioma, Int J Neurosci, 1
- Luo, 2017, Deficiency in Neuronal TGF-beta Signaling Leads to Nigrostriatal Degeneration and Activation of TGF-beta Signaling Protects against MPTP Neurotoxicity in Mice, J Neurosci, 37, 4584, 10.1523/JNEUROSCI.2952-16.2017 · DOI
- Sipper, 2001, Fuzzy CoCo: a cooperative-coevolutionary approach to fuzzy modeling, IEEE Transactions on Fuzzy Systems, 9, 727, 10.1109/91.963759 · DOI
- Pena-Reyes, 2004, Evolutionary fuzzy modeling human diagnostic decisions, Ann N Y Acad Sci, 1020, 190, 10.1196/annals.1310.017 · doi:10.1196/annals.1310.017
- Hatzigeorgiou, 2015, DIANA-miRPath v3.0: deciphering microRNA function with experimental support, Nucleic Acids Res, 43, W460, 10.1093/nar/gkv403 · DOI · Paper page
- Dugger, 2014, Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study, Neurology, 83, 406, 10.1212/WNL.0000000000000641 · DOI · Paper page
- Lefevre, 2012, miRNA_Targets: a database for miRNA target predictions in coding and non-coding regions of mRNAs, Genomics, 100, 352, 10.1016/j.ygeno.2012.08.006 · DOI
- Ambros, 1993, The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14, Cell, 75, 843, 10.1016/0092-8674(93)90529-Y · DOI · Paper page
- Verbeek, 2016, MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy, Mol Neurobiol, 54, 7736
- Gibbard, 1982, The prospective Pareto Principle and equity of access to health care, Milbank Mem Fund Q Health Soc, 60, 399, 10.2307/3349800 · doi:10.2307/3349800
- Alvarez, 2013, Profile of microRNAs in the plasma of Parkinson’s disease patients and healthy controls, J Neurol, 260, 1420, 10.1007/s00415-013-6900-8 · DOI
- Lu, 2010, Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression, Nature, 466, 637, 10.1038/nature09191 · DOI · Paper page
- Jeromin, 2014, CSF alpha-synuclein and UCH-L1 levels in Parkinson’s disease and atypical parkinsonian disorders, Parkinsonism Relat Disord, 20, 382, 10.1016/j.parkreldis.2014.01.011 · DOI
- Hansson, 2015, CSF biomarkers and clinical progression of Parkinson disease, Neurology, 84, 57, 10.1212/WNL.0000000000001098 · DOI · Paper page
- Fernandez, 2015, Correlates of cerebrospinal fluid levels of oligomeric- and total-alpha-synuclein in premotor, motor and dementia stages of Parkinson’s disease, J Neurol, 262, 294, 10.1007/s00415-014-7560-z · DOI
- Lees, 1992, Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases, J Neurol Neurosurg Psychiatry, 55, 181, 10.1136/jnnp.55.3.181 · DOI · Paper page
- Seidl, 2004, Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations, Mov Disord, 19, 1020, 10.1002/mds.20213 · DOI · Paper page
- Feng, 2016, Resting-state functional connectivity of subthalamic nucleus in different Parkinson’s disease phenotypes, J Neurol Sci, 371, 137, 10.1016/j.jns.2016.10.035 · DOI
- Mir, 2017, Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson’s disease subtype, PLoS One, 12, e0174644, 10.1371/journal.pone.0174644 · doi:10.1371/journal.pone.0174644
- Wiltfang, 2006, The German Competence Net Dementias: standard operating procedures for the neurochemical dementia diagnostics, J Neural Transm (Vienna), 113, 1075, 10.1007/s00702-006-0511-9 · DOI
- Salzberg, 2009, Ultrafast and memory-efficient alignment of short DNA sequences to the human genome, Genome Biol, 10, R25, 10.1186/gb-2009-10-3-r25 · DOI · Paper page
- Haussler, 2002, The human genome browser at UCSC, Genome Res, 12, 996, 10.1101/gr.229102 · DOI · Paper page
- Hourlier, 2016, Ensembl 2016, Nucleic Acids Res, 44, D710, 10.1093/nar/gkv1157 · DOI · Paper page
- Jian, 2016, miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database, Nucleic Acids Res, 44, D239, 10.1093/nar/gkv1258 · DOI · Paper page
Cited by
Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors
Emamzadeh, F. N., & Surguchov, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00612 · Cited by 568
Oxidative stress and regulated cell death in Parkinson’s disease
Dionísio, P. A., Amaral, J. D., & Rodrigues, C. M. P. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101263 · Cited by 424
Gámez-Valero, A., Campdelacreu, J., Vilas, D., Ispierto, L., Reñé, R., Álvarez, R., Armengol, M. P., Borràs, F. E., & Beyer, K. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0169-5 · Cited by 167
Exosome Determinants of Physiological Aging and Age-Related Neurodegenerative Diseases
D’Anca, M., Fenoglio, C., Serpente, M., Arosio, B., Cesari, M., Scarpini, E. A., & Galimberti, D. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00232 · Cited by 154
Emergence of Extracellular Vesicles as “Liquid Biopsy” for Neurological Disorders: Boom or Bust
Kumar, A., Nader, M. A., & Deep, G. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000788 · Cited by 79
Metadata
- Authors
- dos Santos, M. C. T., Barreto-Sanz, M. A., Correia, B. R. S., Bell, R., Widnall, C., Perez, L. T., Berteau, C., Schulte, C., Scheller, D., Berg, D., Maetzler, W., Galante, P. A. F., & Nogueira da Costa, A.
- Affiliations
- Experimental Medicine and Diagnostics, Global Exploratory Development, UCB Biopharma SPRL, Braine-l'Alleud, Belgium
- SimplicityBio SA, Monthey, Switzerland
- Hospital Sirio Libanes, São Paulo, Brazil
- Centre for Misfolding Diseases, University of Cambridge, Cambridge, UK
- Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK
- Bioanalytical Sciences, Non Clinical Development, UCB Biopharma SPRL, Belgium
- Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, University of Tuebingen and German Center for Neurodegenerative Diseases, Tuebingen, Germany
- Consultancy Neuropharm, Neukirchener, Neuss, Germany
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2018-04-03
- Volume
- 9
- Issue
- 25
- Pages
- 17455-17465
- ISSN
- 1949-2553
- Cited by
- 120
- References
- 9
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson’s disease. https://app.cochat.ai/papers/10.18632/oncotarget.24736
- The paper
- dos Santos, M. C. T., Barreto-Sanz, M. A., Correia, B. R. S., Bell, R., Widnall, C., Perez, L. T., Berteau, C., Schulte, C., Scheller, D., Berg, D., Maetzler, W., Galante, P. A. F., & Nogueira da Costa, A. (2018). miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson’s disease. Oncotarget. https://doi.org/10.18632/oncotarget.24736
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.